ACLX Arcellx Inc

$71.28

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Arcellx Inc

Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.

Website: https://www.arcellx.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1786205
Address
25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG, MD, US
Valuation
Market Cap
$3.41B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
7.49
Performance
EPS
$-2.00
Dividend Yield
—
Profit Margin
-99.50%
ROE
-22.80%
Technicals
50D MA
$65.39
200D MA
$72.90
52W High
$107.37
52W Low
$47.88
Fundamentals
Shares Outstanding
55M
Target Price
$115.40
Beta
0.33

ACLX EPS Estimates vs Actual

● Estimated
● Actual

ACLX News & Sentiment

Aug 08, 2025 • Motley Fool SOMEWHAT-BULLISH
Gilead Sciences ( GILD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Aug 07, 2025 • Zacks Commentary NEUTRAL
Arcellx, Inc. ( ACLX ) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 07, 2025 • Motley Fool NEUTRAL
Arcellx ( ACLX ) Q2 Revenue Drops 72%
Arcellx ( NASDAQ:ACLX ) , a biotechnology company developing cell therapies for blood cancers and autoimmune diseases, reported its second quarter 2025 results on August 7, 2025. The most notable update centered on a sharp revenue miss and a wider net loss, even as key clinical milestones ...
Jun 30, 2025 • Benzinga SOMEWHAT-BULLISH
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Johnson & Johnson ( NYSE:JNJ ) , Novartis ( NYSE:NVS ) , Gilead Sciences ( NASDAQ:GILD ) , Bristol-Myers Squibb ( NYSE:BMY )
FDA eliminated REMS for six approved CAR-T therapies. Patients no longer need to stay near treatment site for two weeks or avoid driving post-therapy. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July. The U.S.
May 21, 2025 • Benzinga SOMEWHAT-BULLISH
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Arcellx ( NASDAQ:ACLX ) , Akso Health ( NASDAQ:AHG )
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Wednesday. Shares of Dycom Industries, Inc. DY rose sharply during Wednesday's session after the company reported better-than-expected first-quarter financial results, issued second-quarter sales guidance above ...
May 08, 2025 • Zacks Commentary NEUTRAL
Arcellx, Inc. ( ACLX ) Reports Q1 Loss, Lags Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -34.52% and 55.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.212
50 articles with scored sentiment

Overall Sentiment:

Bullish

ACLX Reported Earnings

Feb 28, 2025
Dec 31, 2024 (Pre market)
-0.4 Surprise
  • Reported EPS: $-0.87
  • Estimate: $-0.47
  • Whisper: —
  • Surprise %: -83.4%
Nov 08, 2024
Sep 30, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $-0.48
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: -96.2%
Aug 09, 2024
Jun 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.50
  • Whisper: —
  • Surprise %: -2.0%
May 09, 2024
Mar 31, 2024 (Post market)
0.37 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.51
  • Whisper: —
  • Surprise %: 72.5%
Feb 28, 2024
Dec 31, 2023 (Post market)
1.03 Surprise
  • Reported EPS: $0.42
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: 168.8%
Nov 13, 2023
Sep 30, 2023 (Post market)
-0.27 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.54
  • Whisper: —
  • Surprise %: -50.0%
Aug 14, 2023
Jun 30, 2023 (Post market)
-0.19 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -61.3%
May 08, 2023
Mar 31, 2023 (Post market)
-2.4 Surprise
  • Reported EPS: $-0.58
  • Estimate: $1.82
  • Whisper: —
  • Surprise %: -131.9%
Mar 29, 2023
Dec 31, 2022 (Post market)
-0.34 Surprise
  • Reported EPS: $-0.76
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: -81.0%

Financials